Literature DB >> 32425197

Cardiovascular comorbidities, cardiac injury, and prognosis of COVID-19 in New York City.

Toshiki Kuno1, Mai Takahashi2, Reiichiro Obata2, Tetsuro Maeda2.   

Abstract

Using Mt. Sinai (New York City) EMR health system data, we retrospectively analyzed a cohort of 8438 COVID-19 patients seen between March 1 and April 22, 2020. Risk of intubation and of death rose as a function of increasing age and as a function of greater cardiovascular comorbidity. Combining age and specific comorbidity markers showed patterns suggesting that cardiovascular comorbidities increased relative risks for adverse outcomes most substantially in the younger subjects with progressively diminishing relative effects at older ages.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32425197      PMCID: PMC7227573          DOI: 10.1016/j.ahj.2020.05.005

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


Research letters

Coronavirus disease 2019 (COVID-19) caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2, has spread all around the world since December 2019. As of April 22, its epicenter is New York. Previous studies demonstrated that cardiac injury or comorbidities increased the risk of in-hospital mortality in patients with COVID-19. , The aim of this study is to investigate whether cardiovascular disease or cardiac injury increased the risk of mechanical ventilation or mortality using the electronic medical records (EMR) of Mount Sinai Health System in New York City. We analyzed the EMR of COVID19 positive patients from Mount Sinai Health System which used EPIC electronic health record system from March 1st to April 22nd, 2020. Mount Sinai health system combines 7 hospitals with more than 3800 beds and more that 410 ambulatory practices across metropolitan New York. Among 8438 patients, 54.7% of patients (N = 4616) were admitted to these hospitals. Analysis was performed on April 30th, 2020, which included patients who remained in the hospitals. Age, coronary artery disease (CAD), peripheral artery disease (PAD), heart failure, and cardiac injury as well as necessity of mechanical ventilation and mortality among patients with positive polymerase chain reaction test of COVID-19 were extracted. Cardiac injury was defined as troponin I elevation which was defined as 99th percentile upper reference limit. Patients with cardiac injury were compared with those without troponin I elevation among a total of 5320 patients' measurements (63.0%). Mount Sinai Health System waived institutional review board approval since this research used only deidentified, aggregate-level data. No extramural funding was used to support this work and the authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the paper and its final contents. Among 8438 patients with COVID-19, 8.6% of patients had CAD, 8.1% of patients had PAD, 6.9% of patients had heart failure. Table I shows baseline characteristics of this cohort. 43.5% of patients had troponin I elevation among patients who had troponin I measurements. Table II shows the crude rates of mechanical ventilation and mortality. Patients with a CAD, PAD, or heart failure had significantly higher rates of mechanical ventilation and mortality. Notably, cardiac injury demonstrated significantly higher relative risk (RR) of mechanical ventilation (3.45 [95% confidence interval 2.87-4.14]) and of mortality (5.07 [4.45-5.76]) (Table II). We detected higher rates of mechanical ventilation and mortality in patients with CAD, PAD and heart failure in all age groups except >80 years, with relatively higher RR in younger population (Table II).
Table I

Baseline characteristics of total cohort

Number of patients: % (patient number)8438 patients
Age median [IQR]59 [43, 71]
Male53.9% (4544)
White25.8% (2179)
African American22.7% (1913)
Hypertension28.2% (2380)
Hyperlipidemia17.1% (1446)
Diabetes Mellitus19.0% (1606)
Coronary artery disease8.6% (723)
Peripheral artery disease8.1% (680)
Heart failure6.9% (584)
Chronic kidney disease12.4% (1049)
Dialysis1.7% (140)
Chronic obstructive lung disease2.4% (200)
Asthma8.7% (735)
Cancer7.0% (589)
Human Immunodeficiency Virus1.4% (121)
Table II

Incidence of intubation and mortality for patients with cardio-vascular diseases for COVID-19 patients

Intubation, % (event/total)
Death, % (event/total)
Age GroupWith CADWithout CADRR (95% CI)With CADWithout CADRR (95% CI)
All ages11.6% (84/723)6.2% (475/7715)1.88 (1.52-2.35)30.2% (218/723)13.4% (1035/7715)2.24 (1.98-2.55)
≤ 5016.0% (4/25)3.2% (90/2851)5.07 (2.02-12.7)8.0% (2/25)2.0% (56/2851)4.07 (1.05-15.8)
51-6511.7% (21/179)7.1% (158/2237)1.66 (1.08-2.55)19.0% (34/179)10.4% (233/2237)1.82 (1.32-2.53)
66-8013.8% (45/327)9.4% (165/1751)1.46 (1.07-1.99)31.5% (103/327)21.8% (382/1751)1.44 (1.20-1.73)
≥ 807.3% (14/192)7.1% (62/876)1.03 (0.59-1.80)41.1% (79/192)41.6% (364/876)0.99 (0.82-1.19)
With PADWithout PADRR (95% CI)With PADWithout PADRR (95% CI)
All ages11.3% (77/680)6.2% (482/7758)1.82 (1.45-2.29)23.2% (158/680)14.1% (1095/7758)1.64 (1.42-1.91)
≤ 507.5% (5/67)3.2% (89/2809)2.36 (0.99-5.61)7.5% (5/67)1.9% (53/2809)3.96 (1.63-9.58)
51-6513.0% (25/192)6.9% (154/2224)1.88 (1.27-2.79)15.6% (30/192)10.7% (237/2224)1.47 (1.03-2.08)
66-8013.3% (37/278)9.6% (173/1800)1.38 (0.99-1.93)25.9% (72/278)22.9% (413/1800)1.13 (0.91-1.40)
≥ 807.0% (10/143)7.1% (66/925)0.98 (0.52-1.86)35.7% (51/143)42.4% (392/925)0.84 (0.67-1.06)
With HFWithout HFRR (95% CI)With HFWithout HFRR (95% CI)
All ages14.6% (85/584)6.0% (474/7854)2.41 (1.94-2.99)34.2% (200/584)13.4% (1053/7854)2.55 (2.25-2.90)
≤ 5018.8% (9/48)3.0% (85/2828)6.24 (3.34-11.7)10.4% (5/48)1.8% (53/2828)5.56 (2.33-13.3)
51-6514.1% (20/142)7.0% (159/2274)2.01 (1.31-3.11)24.6% (35/142)10.2% (232/2274)2.42 (1.77-3.30)
66-8019.4% (45/232)8.9% (165/1846)2.17 (1.61-2.93)39.2% (91/232)21.3% (394/1846)1.84 (1.53-2.21)
≥ 806.8% (11/162)7.2% (65/906)0.95 (0.51-1.75)42.6% (69/162)41.3% (374/906)1.03 (0.85-1.25)
With Cardiac InjuryWithout Cardiac InjuryRR (95% CI)With Cardiac InjuryWithout Cardiac InjuryRR (95% CI)
All16.7% (387/2312)4.9% (146/3008)3.45 (2.87-4.14)41.3% (954/2312)8.1% (245/3008)5.07 (4.45-5.76)
≤ 5026.8% (40/149)5.4% (44/819)5.00 (3.38-7.39)23.4% (35/149)2.7% (22/819)8.74 (5.28-14.5)
51-6522.5% (126/561)4.4% (46/1050)5.13 (3.72-7.07)33.0% (185/561)6.7% (70/1050)4.95 (3.83-6.38)
66-8017.4% (157/902)5.5% (47/860)3.18 (2.33-4.35)42.5% (383/902)10.0% (86/860)4.25 (3.43-5.26)
≥ 809.1% (64/700)3.2% (9/279)2.83 (1.43-5.62)50.1% (351/700)24.0% (67/279)2.09 (1.67-2.61)

CAD, coronary artery disease; CI, Confidential interval; HF, heart failure; PAD, peripheral artery disease; RR, relative risk.

Baseline characteristics of total cohort Incidence of intubation and mortality for patients with cardio-vascular diseases for COVID-19 patients CAD, coronary artery disease; CI, Confidential interval; HF, heart failure; PAD, peripheral artery disease; RR, relative risk. Our study revealed increased risk of mechanical ventilation and mortality in patients with cardiovascular comorbidities or cardiac injury. Since we present crude event rates, further study is needed to confirm our findings.
  5 in total

1.  Clinical application of the 4th Universal Definition of Myocardial Infarction.

Authors:  Tau S Hartikainen; Nils Arne Sörensen; Paul Michael Haller; Alina Goßling; Jonas Lehmacher; Tanja Zeller; Stefan Blankenberg; Dirk Westermann; Johannes Tobias Neumann
Journal:  Eur Heart J       Date:  2020-06-14       Impact factor: 29.983

2.  Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China.

Authors:  Shaobo Shi; Mu Qin; Bo Shen; Yuli Cai; Tao Liu; Fan Yang; Wei Gong; Xu Liu; Jinjun Liang; Qinyan Zhao; He Huang; Bo Yang; Congxin Huang
Journal:  JAMA Cardiol       Date:  2020-07-01       Impact factor: 14.676

3.  A Novel Coronavirus from Patients with Pneumonia in China, 2019.

Authors:  Na Zhu; Dingyu Zhang; Wenling Wang; Xingwang Li; Bo Yang; Jingdong Song; Xiang Zhao; Baoying Huang; Weifeng Shi; Roujian Lu; Peihua Niu; Faxian Zhan; Xuejun Ma; Dayan Wang; Wenbo Xu; Guizhen Wu; George F Gao; Wenjie Tan
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

4.  Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis.

Authors:  Jing Yang; Ya Zheng; Xi Gou; Ke Pu; Zhaofeng Chen; Qinghong Guo; Rui Ji; Haojia Wang; Yuping Wang; Yongning Zhou
Journal:  Int J Infect Dis       Date:  2020-03-12       Impact factor: 3.623

5.  Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City.

Authors:  H Miyashita; T Mikami; N Chopra; T Yamada; S Chernyavsky; D Rizk; C Cruz
Journal:  Ann Oncol       Date:  2020-04-21       Impact factor: 32.976

  5 in total
  13 in total

1.  Cardiac Injury and Outcomes of Patients with COVID-19 in New York City.

Authors:  Tetsuro Maeda; Reiichiro Obata; Dahlia Rizk; Toshiki Kuno
Journal:  Heart Lung Circ       Date:  2020-11-23       Impact factor: 2.975

2.  Management of Cardiac Patients During the COVID-19 Pandemic.

Authors:  Günter Breithardt; Hani K Najm; Marko Turina; Ahmed A Arifi
Journal:  J Saudi Heart Assoc       Date:  2020-06-22

3.  ACC Health Policy Statement on Cardiovascular Disease Considerations for COVID-19 Vaccine Prioritization: A Report of the American College of Cardiology Solution Set Oversight Committee.

Authors:  Elissa Driggin; Thomas M Maddox; Keith C Ferdinand; James N Kirkpatrick; Bonnie Ky; Alanna A Morris; J Brendan Mullen; Sahil A Parikh; Daniel M Philbin; Muthiah Vaduganathan
Journal:  J Am Coll Cardiol       Date:  2021-02-12       Impact factor: 24.094

4.  Association of Overlapped and Un-overlapped Comorbidities with COVID-19 Severity and Treatment Outcomes: A Retrospective Cohort Study from Nine Provinces in China.

Authors:  Yan Ma; Dong Shan Zhu; Ren Bo Chen; Nan Nan Shi; Si Hong Liu; Yi Pin Fan; Gui Hui Wu; Pu Ye Yang; Jiang Feng Bai; Hong Chen; Li Ying Chen; Qiao Feng; Tuan Mao Guo; Yong Hou; Gui Fen Hu; Xiao Mei Hu; Yun Hong Hu; Jin Huang; Qiu Hua Huang; Shao Zhen Huang; Liang Ji; Hai Hao Jin; Xiao Lei; Chun Yan Li; Min Qing Li; Qun Tang Li; Xian Yong Li; Hong De Liu; Jin Ping Liu; Zhang Liu; Yu Ting Ma; Ya Mao; Liu Fen Mo; Hui Na; Jing Wei Wang; Fang Li Song; Sheng Sun; Dong Ting Wang; Ming Xuan Wang; Xiao Yan Wang; Yin Zhen Wang; Yu Dong Wang; Wei Wu; Lan Ping Wu; Yan Hua Xiao; Hai Jun Xie; Hong Ming Xu; Shou Fang Xu; Rui Xia Xue; Chun Yang; Kai Jun Yang; Sheng Li Yuan; Gong Qi Zhang; Jin Bo Zhang; Lin Song Zhang; Shu Sen Zhao; Wan Ying Zhao; Kai Zheng; Ying Chun Zhou; Jun Teng Zhu; Tian Qing Zhu; Hua Min Zhang; Yan Ping Wang; Yong Yan Wang
Journal:  Biomed Environ Sci       Date:  2020-12-20       Impact factor: 3.118

5.  COVID-19 and multisystem inflammatory syndrome in children: A systematic review and meta-analysis.

Authors:  Jun Yasuhara; Kae Watanabe; Hisato Takagi; Naokata Sumitomo; Toshiki Kuno
Journal:  Pediatr Pulmonol       Date:  2021-01-11

6.  Impact of COPD on COVID-19 prognosis: A nationwide population-based study in South Korea.

Authors:  Sang Chul Lee; Kang Ju Son; Chang Hoon Han; Seon Cheol Park; Ji Ye Jung
Journal:  Sci Rep       Date:  2021-02-12       Impact factor: 4.379

Review 7.  Prediction of in-hospital mortality with machine learning for COVID-19 patients treated with steroid and remdesivir.

Authors:  Toshiki Kuno; Yuki Sahashi; Shinpei Kawahito; Mai Takahashi; Masao Iwagami; Natalia N Egorova
Journal:  J Med Virol       Date:  2021-10-22       Impact factor: 20.693

8.  Host Factor Interaction Networks Identified by Integrative Bioinformatics Analysis Reveals Therapeutic Implications in COPD Patients With COVID-19.

Authors:  Wenjiang Zheng; Ting Wang; Peng Wu; Qian Yan; Chengxin Liu; Hui Wu; Shaofeng Zhan; Xiaohong Liu; Yong Jiang; Hongfa Zhuang
Journal:  Front Pharmacol       Date:  2021-12-23       Impact factor: 5.810

9.  Coronary artery calcium score may be a novel predictor of COVID-19 prognosis: a retrospective study.

Authors:  Yuichiro Takeshita; Jiro Terada; Retsu Fujita; Yasutaka Hirasawa; Taku Kinoshita; Yuri Isaka; Toru Kinouchi; Hiroshi Tajima; Yuji Tada; Shigeru Kiryu; Kenji Tsushima
Journal:  BMJ Open Respir Res       Date:  2021-07

Review 10.  COVID-19 and COPD.

Authors:  Janice M Leung; Masahiro Niikura; Cheng Wei Tony Yang; Don D Sin
Journal:  Eur Respir J       Date:  2020-08-13       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.